Bayer – Capital Expenditure

Quarterly charts & data from official filings

Timeframe

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:12 May. 26
Capital expenditure:
411,000,000 €-48.5%
Earnings release date:04 Mar. 26
Capital expenditure:
798,000,000 €-4.5%
Earnings release date:12 Nov. 25
Capital expenditure:
836,000,000 €+79.8%
Earnings release date:06 Aug. 25
Capital expenditure:
465,000,000 €+19.8%
Earnings release date:13 May. 25
Capital expenditure:
388,000,000 €-64.7%
Earnings release date:05 Mar. 25
Capital expenditure:
1,099,000,000 €+81.7%
Earnings release date:12 Nov. 24
Capital expenditure:
605,000,000 €-3.7%
Earnings release date:06 Aug. 24
Capital expenditure:
628,000,000 €+40.8%
Earnings release date:14 May. 24
Capital expenditure:
446,000,000 €-55.2%
Earnings release date:05 Mar. 24
Capital expenditure:
996,000,000 €+45.8%
Earnings release date:08 Nov. 23
Capital expenditure:
683,000,000 €+12.7%
Earnings release date:08 Aug. 23
Capital expenditure:
606,000,000 €+30.0%
Earnings release date:11 May. 23
Capital expenditure:
466,000,000 €-64.8%
Earnings release date:28 Feb. 23
Capital expenditure:
1,324,000,000 €+82.4%
Earnings release date:08 Nov. 22
Capital expenditure:
726,000,000 €+32.0%
Earnings release date:04 Aug. 22
Capital expenditure:
550,000,000 €

Revenue by segment

Revenue by segmentTable view

Earnings release date
Crop Science
Pharmaceuticals
Consumer Health
Reconciliation
Total
Earnings release date:12 May. 26
Crop Science:
7,558,000,000 €+40.1%
Pharmaceuticals:
4,249,000,000 €-5.1%
Consumer Health:
1,491,000,000 €+2.1%
Reconciliation:
107,000,000 €+1.9%
Total:
13,405,000,000 €+17.2%
Earnings release date:04 Mar. 26
Crop Science:
5,396,000,000 €+39.9%
Pharmaceuticals:
4,476,000,000 €+3.3%
Consumer Health:
1,461,000,000 €+3.3%
Reconciliation:
105,000,000 €+101.9%
Total:
11,438,000,000 €+18.4%
Earnings release date:12 Nov. 25
Crop Science:
3,858,000,000 €-19.4%
Pharmaceuticals:
4,335,000,000 €-3.0%
Consumer Health:
1,415,000,000 €-0.8%
Reconciliation:
52,000,000 €-3.7%
Total:
9,660,000,000 €-10.0%
Earnings release date:06 Aug. 25
Crop Science:
4,788,000,000 €-36.8%
Pharmaceuticals:
4,470,000,000 €-1.7%
Consumer Health:
1,427,000,000 €-4.8%
Reconciliation:
54,000,000 €-51.4%
Total:
10,739,000,000 €-21.8%
Earnings release date:13 May. 25
Crop Science:
7,580,000,000 €+40.8%
Pharmaceuticals:
4,548,000,000 €-2.4%
Consumer Health:
1,499,000,000 €-4.3%
Reconciliation:
111,000,000 €-6.7%
Total:
13,738,000,000 €+17.1%
Earnings release date:05 Mar. 25
Crop Science:
5,385,000,000 €+35.1%
Pharmaceuticals:
4,658,000,000 €+3.3%
Consumer Health:
1,567,000,000 €+10.9%
Reconciliation:
119,000,000 €+101.7%
Total:
11,729,000,000 €+17.7%
Earnings release date:12 Nov. 24
Crop Science:
3,986,000,000 €-20.0%
Pharmaceuticals:
4,510,000,000 €-2.1%
Consumer Health:
1,413,000,000 €-3.1%
Reconciliation:
59,000,000 €-41.0%
Total:
9,968,000,000 €-10.6%
Earnings release date:06 Aug. 24
Crop Science:
4,981,000,000 €-37.0%
Pharmaceuticals:
4,605,000,000 €+5.7%
Consumer Health:
1,458,000,000 €+1.8%
Reconciliation:
100,000,000 €+47.1%
Total:
11,144,000,000 €-19.0%
Earnings release date:14 May. 24
Crop Science:
7,907,000,000 €+40.4%
Pharmaceuticals:
4,358,000,000 €-4.8%
Consumer Health:
1,432,000,000 €-9.3%
Reconciliation:
68,000,000 €-9.3%
Total:
13,765,000,000 €+16.0%
Earnings release date:05 Mar. 24
Crop Science:
5,630,000,000 €+29.0%
Pharmaceuticals:
4,579,000,000 €+0.9%
Consumer Health:
1,578,000,000 €+11.9%
Reconciliation:
75,000,000 €+158.6%
Total:
11,862,000,000 €+14.7%
Earnings release date:08 Nov. 23
Crop Science:
4,365,000,000 €-11.4%
Pharmaceuticals:
4,538,000,000 €-0.4%
Consumer Health:
1,410,000,000 €-3.8%
Reconciliation:
29,000,000 €-70.1%
Total:
10,342,000,000 €-6.4%
Earnings release date:08 Aug. 23
Crop Science:
4,924,000,000 €-41.0%
Pharmaceuticals:
4,557,000,000 €+3.4%
Consumer Health:
1,466,000,000 €-6.8%
Reconciliation:
97,000,000 €+67.2%
Total:
11,044,000,000 €-23.2%
Earnings release date:11 May. 23
Crop Science:
8,351,000,000 €+50.0%
Pharmaceuticals:
4,407,000,000 €-9.2%
Consumer Health:
1,573,000,000 €+3.2%
Reconciliation:
58,000,000 €+11.5%
Total:
14,389,000,000 €+19.9%
Earnings release date:28 Feb. 23
Crop Science:
5,569,000,000 €+18.7%
Pharmaceuticals:
4,855,000,000 €-2.0%
Consumer Health:
1,524,000,000 €-1.6%
Reconciliation:
52,000,000 €-39.5%
Total:
12,000,000,000 €+6.4%
Earnings release date:08 Nov. 22
Crop Science:
4,692,000,000 €-27.4%
Pharmaceuticals:
4,955,000,000 €+2.8%
Consumer Health:
1,548,000,000 €+3.5%
Reconciliation:
86,000,000 €+95.5%
Total:
11,281,000,000 €-12.0%
Earnings release date:04 Aug. 22
Crop Science:
6,461,000,000 €
Pharmaceuticals:
4,818,000,000 €
Consumer Health:
1,496,000,000 €
Reconciliation:
44,000,000 €
Total:
12,819,000,000 €

Revenue by geographic location

Revenue by geographic locationTable view

Earnings release date
Europe/Middle East/Africa
North America
Asia/Pacific
Latin America
Total
Earnings release date:12 May. 26
Europe/Middle East/Africa:
4,081,000,000 €+42.2%
North America:
6,045,000,000 €+49.1%
Asia/Pacific:
1,901,000,000 €+6.7%
Latin America:
1,378,000,000 €-49.6%
Total:
13,405,000,000 €+17.2%
Earnings release date:04 Mar. 26
Europe/Middle East/Africa:
2,869,000,000 €-1.8%
North America:
4,054,000,000 €+48.6%
Asia/Pacific:
1,782,000,000 €+7.7%
Latin America:
2,733,000,000 €+16.1%
Total:
11,438,000,000 €+18.4%
Earnings release date:12 Nov. 25
Europe/Middle East/Africa:
2,923,000,000 €-11.6%
North America:
2,729,000,000 €-33.8%
Asia/Pacific:
1,655,000,000 €-17.3%
Latin America:
2,353,000,000 €+79.3%
Total:
9,660,000,000 €-10.0%
Earnings release date:06 Aug. 25
Europe/Middle East/Africa:
3,305,000,000 €-25.0%
North America:
4,120,000,000 €-29.2%
Asia/Pacific:
2,002,000,000 €-3.7%
Latin America:
1,312,000,000 €-8.4%
Total:
10,739,000,000 €-21.8%
Earnings release date:13 May. 25
Europe/Middle East/Africa:
4,404,000,000 €+48.3%
North America:
5,822,000,000 €+45.8%
Asia/Pacific:
2,079,000,000 €-3.5%
Latin America:
1,433,000,000 €-45.1%
Total:
13,738,000,000 €+17.1%
Earnings release date:05 Mar. 25
Europe/Middle East/Africa:
2,969,000,000 €-1.7%
North America:
3,994,000,000 €+55.5%
Asia/Pacific:
2,155,000,000 €+13.7%
Latin America:
2,611,000,000 €+5.1%
Total:
11,729,000,000 €+17.7%
Earnings release date:12 Nov. 24
Europe/Middle East/Africa:
3,020,000,000 €-13.7%
North America:
2,569,000,000 €-38.2%
Asia/Pacific:
1,895,000,000 €-10.1%
Latin America:
2,484,000,000 €+79.6%
Total:
9,968,000,000 €-10.6%
Earnings release date:06 Aug. 24
Europe/Middle East/Africa:
3,500,000,000 €-22.1%
North America:
4,154,000,000 €-27.9%
Asia/Pacific:
2,107,000,000 €+10.1%
Latin America:
1,383,000,000 €-13.6%
Total:
11,144,000,000 €-19.0%
Earnings release date:14 May. 24
Europe/Middle East/Africa:
4,491,000,000 €+45.6%
North America:
5,760,000,000 €+52.0%
Asia/Pacific:
1,914,000,000 €-7.4%
Latin America:
1,600,000,000 €-45.2%
Total:
13,765,000,000 €+16.0%
Earnings release date:05 Mar. 24
Europe/Middle East/Africa:
3,085,000,000 €+1.0%
North America:
3,789,000,000 €+50.3%
Asia/Pacific:
2,067,000,000 €+9.6%
Latin America:
2,921,000,000 €+1.4%
Total:
11,862,000,000 €+14.7%
Earnings release date:08 Nov. 23
Europe/Middle East/Africa:
3,055,000,000 €-7.6%
North America:
2,521,000,000 €-37.6%
Asia/Pacific:
1,886,000,000 €-15.6%
Latin America:
2,880,000,000 €+96.7%
Total:
10,342,000,000 €-6.4%
Earnings release date:08 Aug. 23
Europe/Middle East/Africa:
3,307,000,000 €-28.7%
North America:
4,038,000,000 €-31.6%
Asia/Pacific:
2,235,000,000 €+2.5%
Latin America:
1,464,000,000 €-12.0%
Total:
11,044,000,000 €-23.2%
Earnings release date:11 May. 23
Europe/Middle East/Africa:
4,639,000,000 €+51.2%
North America:
5,906,000,000 €+50.0%
Asia/Pacific:
2,181,000,000 €-4.5%
Latin America:
1,663,000,000 €-38.7%
Total:
14,389,000,000 €+19.9%
Earnings release date:28 Feb. 23
Europe/Middle East/Africa:
3,068,000,000 €-4.4%
North America:
3,937,000,000 €+37.9%
Asia/Pacific:
2,283,000,000 €+0.8%
Latin America:
2,712,000,000 €-8.2%
Total:
12,000,000,000 €+6.4%
Earnings release date:08 Nov. 22
Europe/Middle East/Africa:
3,208,000,000 €-11.8%
North America:
2,855,000,000 €-40.7%
Asia/Pacific:
2,265,000,000 €-9.1%
Latin America:
2,953,000,000 €+57.8%
Total:
11,281,000,000 €-12.0%
Earnings release date:04 Aug. 22
Europe/Middle East/Africa:
3,639,000,000 €
North America:
4,817,000,000 €
Asia/Pacific:
2,492,000,000 €
Latin America:
1,871,000,000 €
Total:
12,819,000,000 €

Operating expenses

Operating expensesTable view

Earnings release date
Cost of goods sold
Selling expenses
Research and development expenses
General administration expenses
Total
Earnings release date:12 May. 26
Cost of goods sold:
5,232,000,000 €+16.2%
Selling expenses:
3,164,000,000 €-7.9%
Research and development expenses:
1,419,000,000 €+1.0%
General administration expenses:
532,000,000 €-13.8%
Total:
10,347,000,000 €+3.9%
Earnings release date:04 Mar. 26
Cost of goods sold:
4,501,000,000 €+4.5%
Selling expenses:
3,435,000,000 €+17.5%
Research and development expenses:
1,405,000,000 €-6.2%
General administration expenses:
617,000,000 €+28.0%
Total:
9,958,000,000 €+8.1%
Earnings release date:12 Nov. 25
Cost of goods sold:
4,307,000,000 €-1.3%
Selling expenses:
2,923,000,000 €-3.6%
Research and development expenses:
1,498,000,000 €+6.4%
General administration expenses:
482,000,000 €-6.0%
Total:
9,210,000,000 €-1.1%
Earnings release date:06 Aug. 25
Cost of goods sold:
4,364,000,000 €-22.4%
Selling expenses:
3,032,000,000 €-4.0%
Research and development expenses:
1,408,000,000 €-3.4%
General administration expenses:
513,000,000 €-6.4%
Total:
9,317,000,000 €-13.7%
Earnings release date:13 May. 25
Cost of goods sold:
5,625,000,000 €-1.7%
Selling expenses:
3,159,000,000 €-12.2%
Research and development expenses:
1,458,000,000 €-15.5%
General administration expenses:
548,000,000 €-25.5%
Total:
10,790,000,000 €-8.4%
Earnings release date:05 Mar. 25
Cost of goods sold:
5,723,000,000 €+12.4%
Selling expenses:
3,599,000,000 €+14.0%
Research and development expenses:
1,725,000,000 €+10.6%
General administration expenses:
736,000,000 €+29.8%
Total:
11,783,000,000 €+13.6%
Earnings release date:12 Nov. 24
Cost of goods sold:
5,090,000,000 €+1.9%
Selling expenses:
3,158,000,000 €-6.1%
Research and development expenses:
1,559,000,000 €+4.0%
General administration expenses:
567,000,000 €-17.6%
Total:
10,374,000,000 €-1.6%
Earnings release date:06 Aug. 24
Cost of goods sold:
4,994,000,000 €-8.6%
Selling expenses:
3,362,000,000 €+3.6%
Research and development expenses:
1,499,000,000 €+5.1%
General administration expenses:
688,000,000 €+18.0%
Total:
10,543,000,000 €-1.6%
Earnings release date:14 May. 24
Cost of goods sold:
5,463,000,000 €+21.8%
Selling expenses:
3,245,000,000 €+14.3%
Research and development expenses:
1,426,000,000 €+33.3%
General administration expenses:
583,000,000 €-22.8%
Total:
10,717,000,000 €+17.1%
Earnings release date:05 Mar. 24
Cost of goods sold:
4,486,000,000 €-6.8%
Selling expenses:
2,839,000,000 €-7.0%
Research and development expenses:
1,070,000,000 €-28.8%
General administration expenses:
755,000,000 €+37.0%
Total:
9,150,000,000 €-7.7%
Earnings release date:08 Nov. 23
Cost of goods sold:
4,812,000,000 €+2.0%
Selling expenses:
3,053,000,000 €-4.5%
Research and development expenses:
1,502,000,000 €+22.3%
General administration expenses:
551,000,000 €+12.7%
Total:
9,918,000,000 €+3.0%
Earnings release date:08 Aug. 23
Cost of goods sold:
4,718,000,000 €-17.7%
Selling expenses:
3,196,000,000 €-5.8%
Research and development expenses:
1,228,000,000 €-21.8%
General administration expenses:
489,000,000 €-25.7%
Total:
9,631,000,000 €-15.2%
Earnings release date:11 May. 23
Cost of goods sold:
5,733,000,000 €+20.2%
Selling expenses:
3,394,000,000 €-8.4%
Research and development expenses:
1,571,000,000 €-2.7%
General administration expenses:
658,000,000 €-8.6%
Total:
11,356,000,000 €+5.1%
Earnings release date:28 Feb. 23
Cost of goods sold:
4,768,000,000 €+12.3%
Selling expenses:
3,706,000,000 €+10.4%
Research and development expenses:
1,614,000,000 €+2.4%
General administration expenses:
720,000,000 €-0.1%
Total:
10,808,000,000 €+9.1%
Earnings release date:08 Nov. 22
Cost of goods sold:
4,247,000,000 €-25.2%
Selling expenses:
3,358,000,000 €-10.1%
Research and development expenses:
1,576,000,000 €-18.3%
General administration expenses:
721,000,000 €-2.0%
Total:
9,902,000,000 €-18.0%
Earnings release date:04 Aug. 22
Cost of goods sold:
5,680,000,000 €
Selling expenses:
3,736,000,000 €
Research and development expenses:
1,928,000,000 €
General administration expenses:
736,000,000 €
Total:
12,080,000,000 €

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:12 May. 26
Net income (shareholders):
2,763,000,000 €+173.5%
Free cash flow:
-2,205,000,000 €-164.8%
Total:
558,000,000 €+258.1%
Earnings release date:04 Mar. 26
Net income (shareholders):
-3,757,000,000 €-290.1%
Free cash flow:
3,404,000,000 €+300.9%
Total:
-353,000,000 €-209.6%
Earnings release date:12 Nov. 25
Net income (shareholders):
-963,000,000 €-383.9%
Free cash flow:
849,000,000 €+43.2%
Total:
-114,000,000 €-128.9%
Earnings release date:06 Aug. 25
Net income (shareholders):
-199,000,000 €-115.3%
Free cash flow:
593,000,000 €+142.3%
Total:
394,000,000 €+478.8%
Earnings release date:13 May. 25
Net income (shareholders):
1,299,000,000 €+487.8%
Free cash flow:
-1,403,000,000 €-136.0%
Total:
-104,000,000 €-102.9%
Earnings release date:05 Mar. 25
Net income (shareholders):
-335,000,000 €+92.0%
Free cash flow:
3,898,000,000 €+158.8%
Total:
3,563,000,000 €+233.1%
Earnings release date:12 Nov. 24
Net income (shareholders):
-4,183,000,000 €-12202.9%
Free cash flow:
1,506,000,000 €-15.5%
Total:
-2,677,000,000 €-253.1%
Earnings release date:06 Aug. 24
Net income (shareholders):
-34,000,000 €-101.7%
Free cash flow:
1,782,000,000 €+168.6%
Total:
1,748,000,000 €+393.3%
Earnings release date:14 May. 24
Net income (shareholders):
2,000,000,000 €+49.6%
Free cash flow:
-2,596,000,000 €-156.3%
Total:
-596,000,000 €-110.0%
Earnings release date:05 Mar. 24
Net income (shareholders):
1,337,000,000 €+129.3%
Free cash flow:
4,611,000,000 €+143.6%
Total:
5,948,000,000 €+322.3%
Earnings release date:08 Nov. 23
Net income (shareholders):
-4,569,000,000 €-142.1%
Free cash flow:
1,893,000,000 €+1651.6%
Total:
-2,676,000,000 €-33.2%
Earnings release date:08 Aug. 23
Net income (shareholders):
-1,887,000,000 €-186.6%
Free cash flow:
-122,000,000 €+97.0%
Total:
-2,009,000,000 €-9.3%
Earnings release date:11 May. 23
Net income (shareholders):
2,178,000,000 €+256.5%
Free cash flow:
-4,016,000,000 €-331.2%
Total:
-1,838,000,000 €-178.3%
Earnings release date:28 Feb. 23
Net income (shareholders):
611,000,000 €+11.9%
Free cash flow:
1,737,000,000 €-9.9%
Total:
2,348,000,000 €-5.1%
Earnings release date:08 Nov. 22
Net income (shareholders):
546,000,000 €+283.2%
Free cash flow:
1,928,000,000 €+24.1%
Total:
2,474,000,000 €+97.0%
Earnings release date:04 Aug. 22
Net income (shareholders):
-298,000,000 €
Free cash flow:
1,554,000,000 €
Total:
1,256,000,000 €

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:12 May. 26
Profit margin (shareholders):
20.61 %+53.5 pp
Profit margin (free cash flow):
-16.45 %-46.2 pp
Earnings release date:04 Mar. 26
Profit margin (shareholders):
-32.85 %-22.9 pp
Profit margin (free cash flow):
29.76 %+21.0 pp
Earnings release date:12 Nov. 25
Profit margin (shareholders):
-9.97 %-8.1 pp
Profit margin (free cash flow):
8.79 %+3.3 pp
Earnings release date:06 Aug. 25
Profit margin (shareholders):
-1.85 %-11.3 pp
Profit margin (free cash flow):
5.52 %+15.7 pp
Earnings release date:13 May. 25
Profit margin (shareholders):
9.46 %+12.3 pp
Profit margin (free cash flow):
-10.21 %-43.4 pp
Earnings release date:05 Mar. 25
Profit margin (shareholders):
-2.86 %+39.1 pp
Profit margin (free cash flow):
33.23 %+18.1 pp
Earnings release date:12 Nov. 24
Profit margin (shareholders):
-41.96 %-41.7 pp
Profit margin (free cash flow):
15.11 %-0.9 pp
Earnings release date:06 Aug. 24
Profit margin (shareholders):
-0.31 %-14.8 pp
Profit margin (free cash flow):
15.99 %+34.9 pp
Earnings release date:14 May. 24
Profit margin (shareholders):
14.53 %+3.3 pp
Profit margin (free cash flow):
-18.86 %-57.7 pp
Earnings release date:05 Mar. 24
Profit margin (shareholders):
11.27 %+55.5 pp
Profit margin (free cash flow):
38.87 %+20.6 pp
Earnings release date:08 Nov. 23
Profit margin (shareholders):
-44.18 %-27.1 pp
Profit margin (free cash flow):
18.3 %+19.4 pp
Earnings release date:08 Aug. 23
Profit margin (shareholders):
-17.09 %-32.2 pp
Profit margin (free cash flow):
-1.1 %+26.8 pp
Earnings release date:11 May. 23
Profit margin (shareholders):
15.14 %+10.0 pp
Profit margin (free cash flow):
-27.91 %-42.4 pp
Earnings release date:28 Feb. 23
Profit margin (shareholders):
5.09 %+0.3 pp
Profit margin (free cash flow):
14.47 %-2.6 pp
Earnings release date:08 Nov. 22
Profit margin (shareholders):
4.84 %+7.2 pp
Profit margin (free cash flow):
17.09 %+5.0 pp
Earnings release date:04 Aug. 22
Profit margin (shareholders):
-2.32 %
Profit margin (free cash flow):
12.12 %